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Abstract
Purpose The Cap-Score™ was developed to assess the capacitation status of men, thereby enabling personalized management of unexplained infertility by choosing timed intrauterine
insemination (IUI), versus immediate in vitro fertilization
(IVF) or intracytoplasmic sperm injection (ICSI) in individuals with a low Cap-Score™. The objective of this study was
to estimate the differences in outcomes and costs comparing
the use of the Cap-Score™ with timed IUI (CS-TI) and the
standard of care (SOC), which was assumed to be three IUI
cycles followed by three IVF-ICSI cycles.
Methods We developed and parameterized a decision-analytic
model of management of unexplained infertility for women
based on data from the published literature. We calculated the
clinical pregnancy rates, live birth rates, and medical costs
comparing CS-TI and SOC. We used Monte Carlo simulation
to quantify uncertainty in projected estimates and performed
univariate sensitivity analysis.
Results Compared to SOC, CS-TI was projected to increase
the pregnancy rate by 1–26%, marginally reduce live birth
rates by 1–3% in couples with women below 40 years,
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increase live birth rates by 3–7% in couples with women over
40 years, reduce mean medical costs by $4000–$19,200, reduce IUI costs by $600–$1370, and reduce IVF costs by
$3400–$17,800, depending on the woman’s age.
Conclusion The Cap-Score™ is a potentially valuable clinical
tool for management of unexplained infertility because it is
projected to improve clinical pregnancy rates, save money,
and, depending on the price of the test, increase access to
treatment for infertility.
Keywords Sperm capacitation . Costs . Clinical pregnancy .
Live births . Decision-analytic modeling

Introduction
The median global prevalence of infertility, defined as the
inability to get pregnant after at least 12 consecutive months
of unprotected sex, is approximately 9–15% [1, 2]. This corresponds to somewhere from 40 to 70 million couples [1, 2].
In the USA, approximately one million women are infertile by
this definition [3]. However, a larger number of women, 7.5
million, have impaired fecundity—the reduced ability to get
pregnant or carry a baby to term [3]. Among men, some 9.4%
are sub-fertile or non-surgically sterile [4].
Of the couples who are unable to conceive, a male factor is
present in 20–70% [5]. As many as 50% of the cases of male
factor infertility are undetectable using traditional semen analysis, which includes sperm count, sperm motility, and sperm
morphology. On the whole, up to 30% of infertile couples
have unexplained infertility: infertility for which the underlying cause is unknown [6, 7]. The underlying cause of unexplained infertility may be oocyte- or sperm-related. Spermrelated causes of unexplained infertility are thought to include
occult sperm abnormalities not detectable through routine
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semen analysis, but are often presumed after repeated failed
cycles of intrauterine insemination (IUI) [8].
Sperm can go through several selection processes prior to
traditional IVF, including density gradient centrifugation and
swim-up protocols [9]. These processes can increase the concentration of sperm capable of fertilization, making it more
likely to have success in traditional IVF when compared to
IUI and natural conception. Nonetheless, some couples with
male factor infertility have a decreased ability to generate
embryos and pregnancies [10]. The men in these couples likely have reduced sperm function related to the failure of sperm
capacitation. Therefore, at the intersection between infertility
with a male factor and unexplained infertility lies a potential
sperm-related cause of infertility—failure of sperm
capacitation.
Sperm capacitation consists of the functional maturation of
sperm membranes triggered by stimuli in the female genital
tract. Capacitation results in a change in the pattern of sperm
motility, known as hyperactivation. Capacitation precedes and
is a precondition for the acrosome reaction and is required for
fertilization. The timing of capacitation occurs differentially
among men but consistently within men [11]. Because of this,
capacitation timing can be utilized to personalize natural conception as well as assisted reproductive technologies (ART)
by optimizing the timing for IUI relative to ovulation and
timing of co-incubation in sperm and oocytes for in vitro fertilization (IVF).
The Cap-Score™ is an in vitro, laboratory-developed test
designed to assess sperm capacitation. The Cap-Score™ evaluates the localization patterns of the ganglioside GM1 to assess the fertilizing ability of sperm. Sperm are incubated in a
non-capacitating (non-Cap) medium and a medium containing capacitating stimuli (Cap). The sperm that respond to the
capacitation stimuli are identified by specific GM1 localization patterns within their plasma membrane. The final readout—the BCap-Score^—is the proportion of sperm within an
ejaculate displaying the GM1 localization patterns reflecting
capacitation [12].
There is little agreement on cutoffs for lower limits of semen variables in fertile men, and proposals have included the
10th centile [13–16], the 5th centile [17–19], and the 2.5th
centile [20]. It has been demonstrated that Cap-Score™ results
follow a normal distribution with 68% of values within one
standard deviation (SD) of the mean, resulting in approximately 16% of observations being below one SD of the mean
[21]. For the purposes of this study, a low Cap-Score™ was
defined as a score of 27.6% which is one SD below the mean
Cap-Score™ of a fertile population (Z score of − 1), a threshold that can be used to identify samples from men with impaired capacitation ability. We chose this to be conservative in
order to minimize the risk that an individual with a borderline
score would be identified as potentially having impaired
sperm function. Such a cutoff has been reported in another

population of men identified with sperm functional abnormalities as to expect them to be infertile in the general population
[5] and has been used by others [22].
Details on the performance of the Cap-Score™ have been
published elsewhere [12]. Briefly, sperm are collected, liquefied, and removed from the seminal plasma. The sperm concentration is adjusted to 10 × 106/mL in total volume of
300 μL, and the samples are incubated in the presence or
absence of BCap^ or capacitation stimulus. Following incubation, the cells are fixed and labeled with Alexa Fluor 488conjugated cholera toxin beta subunit to visualize GM1 localization patterns within the sperm plasma membrane. The GM1
localization patterns are determined for 150 sperm and the
Cap-Score is calculated as the proportion of sperm within
the ejaculate having capacitated patterns.
The objective of this study was to assess the potential clinical and cost impact of the Cap-Score™. We estimated the
differences in clinical pregnancy rates, live birth rates, and
medical costs comparing the use of the Cap-Score™ with
timed IUI (CS-TI) and the current standard of care (SOC) in
which the Cap-Score™ is absent.

Methods
We used decision-analytic modeling methods to estimate the
cost and outcome implications of introducing the CapScore™ into the practice setting for unexplained infertility.
The target population in the model is couples with unexplained infertility.
We compared two possible clinical courses of action
(comparators) (Fig. 1): (1) the Cap-Score and timed intrauterine insemination (CS-TI) and (2) the standard of care (SOC).
In the SOC, we assumed that the couple would undergo three
rounds of IUI followed by three rounds of IVF with
intracytoplasmic sperm injection (ICSI). This is considered
to be the general standard of practice when couples are paying
and this threshold has been used by others in the literature
[21]. In the CS-TI arm, the male would start by providing
sperm for a Cap-Score™. A low Cap-Score™ was assumed
to trigger three rounds of IVF with ICSI without IUI. A normal Cap-Score™ was assumed to trigger three rounds of
timed IUI followed by three rounds of IVF with ICSI. The
outcomes of the model were cumulative probability of live
birth, cumulative probability of clinical pregnancy, total medical costs, IUI costs, and IVF costs.
Probabilities
To estimate the probabilities of fertility-related events, we
used data from publicly-available and published sources
(Table 1). The probabilities of clinical pregnancy per cycle
were modeled as maternal age-dependent and were obtained
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Fig. 1 Decision tree of the outcomes of clinical management of unexplained infertility. UEI unexplained infertility, SOC standard of care, CS + TI capscore + timed insemination, CS cap-score, IUI intrauterine insemination, IVF in vitro fertilization, ICSI intracytoplasmic sperm injection

from the study by Stone et al. [23] for IUI and from the online
database of the Society for Artificial Reproductive
Technology (SART) [24] for IVF. The probability of men
having a low Cap-Score™ was obtained from clinical studies
[21]. The probability of clinical pregnancy with IUI following
a normal Cap-Score™ was assumed to be independent of
maternal age [25]. The probabilities of live birth by comparator, conditional upon being clinically pregnant, were also
modeled as maternal age-dependent, and were obtained from
the study by Stone et al. [23] and the SART database [24] for
IUI and IVF, respectively. For sensitivity analysis ranges, we
used 95% confidence intervals when available, and when unavailable, we used ranges equivalent to +/− 20% for the CapScore, and +/− 50% for variations in the probability of IUI
success.
Costs
The perspective of the cost analysis was that of the social
opportunity cost: i.e., all the costs of ART are included as
reflected in market transaction prices whether paid by patients or third-party payers. This perspective was used because approximately 20% of US states mandate full or
partial payments for ART, and most patients must pay a
proportion or all of the costs of ART out of pocket [26].
To estimate the costs of IUI, given the wide state and regional variation, we used multiple sources including a public website [27] and expert opinion. The baseline cost of
IUI considers the average cost of Clomid medication,

injectable fertility medications for injectable follicle stimulating hormone (FSH) cycles, and costs of monitored injectable FSH cycles (blood tests and ultrasounds). The cost
of IVF was obtained from the study by Chambers et al.
[28] adjusted to 2016 US dollars. This cost includes the
cost of ICSI. The Cap-Score Test™ has not yet been
launched, and no price has been established. Therefore,
we are only able to report cost-offsets that would accrue
as savings gains, whatever the ultimate price. All costs are
in 2016 US dollars and are shown in Table 1.
Analyses and sensitivity analyses
The base case analysis consisted of estimating the mean cumulative probability of pregnancy, the mean cumulative probability of live birth, IUI costs, IVF costs, and total costs comparing CS-TI and SOC. As a measure of the precision of
estimates, we calculated 95% credibility intervals (CIs) by
defining probability distributions for each parameter estimate
and using 10,000 runs of Monte Carlo simulation. Monte
Carlo simulation is a method of analysis of parameter uncertainty in which multiple runs of a model are estimated, with
each run drawing from the distribution of each of a set of
parameter values. The results of the multiple runs produce a
distribution of outcome values, thereby allowing analysts to
produce estimates of the impact of parameter uncertainty on
model results. We used beta distributions for probabilities and
normal distributions for costs. We also assessed parameter
uncertainty by performing univariate sensitivity analyses,
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Table 1 Parameter estimates
used in the model

Baseline

Sensitivity range

Referencea

IUI
IVF-ICSI

$2550
$17,651

$1275–$3825
$8825–$26,476

Expert opinion
[28]

Probabilities
Low Cap-Score Test

0.336

0.269–0.403

[35]

< 35 years
35–37 years

0.161
0.136

0.081–0.242
0.068–0.204

[23]
[23]

38–40 years
41–42 years

0.118
0.068

0.059–0.177
0.034–0.102

[23]
[23]

> 42 years

0.035

0.018–0.053

[23]

With IUI after Cap-Score Test
With IVF-ICSI

0.400

0.320–0.480

Expert opinion

< 35 years
35–37 years
38–40 years
41–42 years
> 42 years
Live birth (per cycle)c
With IUI
< 35 years
35–37 years

0.506
0.445
0.320
0.224
0.121

0.405–0.607
0.356–0.534
0.256–0.384
0.179–0.269
0.097–0.145

[24]b
[24]b
[24]b
[24]b
[24]b

0.559
0.495

0.279–0.838
0.248–0.743

[23]
[23]

38–40 years
41–42 years
> 42 years
With IVF-ICSI
< 35 years
35–37 years
38–40 years
41–42 years
> 42 years

0.462
0.400
0.386

0.231–0.692
0.200–0.600
0.193–0.579

[23]
[23]
[23]

0.879
0.829
0.772
0.594
0.496

0.854–0.903
0.793–0.865
0.722–0.822
0.500–0.688
0.324–0.670

[24]b
[24]b
[24]b
[24]b
[24]b

Parameter
Costs

Clinical pregnancy (per cycle)
With IUI in SOC

a

Represents 95% confidence interval or low and high estimates from multiple studies where data are available and
+/− 50% for both costs and probabilities where data are unavailable or uncertainty is substantial

b

Primary outcome per intended egg retrieval with all cycles as the denominator

c

Conditional upon clinical pregnancy

varying individual parameters with all other parameters in the
model held constant.

Results
Baseline analysis
The results of the baseline analysis are presented in Tables 2
and 3. Compared to SOC, CS-TI is projected to increase the
cumulative clinical pregnancy rates across all age groups. The
magnitude of this increase ranges from a 1% increase in

couples with women under 35 years to 26% in couples with
women over 42 years. Compared to SOC, CS-TI led to marginal reductions in the cumulative live birth rate ranging from
1% in couples with women of between 38 and 40 years and
3% in couples with women under 35 years of age. In couples
with women over 40 years of age, CS-TI results in increased
cumulative live birth rates of between 3% in couples with
women of 41 and 42 years of age and 7% in couple with
women over 42 years of age.
Compared to SOC, CS-TI is projected to reduce cumulative mean number of IUIs and IVFs as well as the total costs of
fertility treatment across all age groups. Mean IUI cost savings
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Table 2

Mean (95% CI) cumulative live birth rate and clinical pregnancy rate comparing SOC to CS-TI

Age (years)

Clinical pregnancy rate

Live birth rate

SOC

CS-TI

< 35
35–37

92.88% (86.97–96.65%)
88.97% (81.94–93.81%)

94.22% (89.59–97.12%)
91.80% (87.08–95.48%)

38–40

78.43% (70.32–85.26%)

84.93% (79.51–89.55%)

41–42
> 42

62.17% (54.16–69.38%)
38.97% (33.03–45.10%)

77.60% (64.76–84.65%)
64.83% (55.44–71.04%)

Δ

SOC

CS-TI

Δ

68.54% (54.11–79.72%)
61.90% (50.74–71.89%)

66.16% (51.09–80.30%)
58.72% (45.15–71.73%)

− 2.38%
− 3.18%

5.29%

50.81% (41.65–59.77%)

49.42% (36.27–62.74%)

− 1.13%

15.43%
25.86%

33.23% (26.45–40.26%)
17.71% (12.37–24.61%)

35.99% (26.76–47.05%)
24.44% (17.11–39.53%)

2.76%
6.73%

1.34%
2.83%

CI credibility interval, SOC standard of care, CS-TI Cap-Score™ with timed intrauterine insemination, Δ change

are projected to vary from $595 in couples with women under
35 years of age to $1366 in couples with women over 42 years
of age. Mean IVF cost savings are projected to vary from
$3410 in couples with women under 35 years of age to
$17,823 in couples with women over 42 years of age. Mean
total cost savings are projected to vary from $4000 in couples
with women under 35 years of age to $19,100 in couples with
women over 42 years of age.
Sensitivity analysis
The projected change in the cumulative probability of clinical
pregnancy comparing CS-TI and SOC was most sensitive to
the probability of clinical pregnancy with IUI in the absence of
the Cap-Score™ for couples with women under 42 years of
age and most sensitive to the probability of a low Cap-Score™
for couples with women over 42 years of age.
The projected change in the cumulative probability of live
births comparing CS-TI and SOC was most sensitive to the
probability of clinical pregnancy with IUI in the absence of the
Cap-Score™ for couples with women under 35 years of age
and most sensitive to the probability of a live birth with IUI for
couples with women over 35 years of age.
The projected reduction in IUI costs comparing CS-TI and
SOC was most sensitive to the probability of clinical pregnancy with IUI in the absence of the Cap-Score™ for couples
with women under 40 years of age and most sensitive to the
cost of IUI for couples with women over 40 years of age.
The projected reduction in IVF costs comparing CS-TI and
SOC was most sensitive to the probability of clinical pregnancy with IUI in the absence of the Cap-Score™ for couples
with women under 40 years of age and most sensitive to the
cost of IVF for couples with women over 40 years of age.
The projected reduction in total costs comparing CS-TI and
SOC was most sensitive to the probability of clinical pregnancy with IUI in the absence of the Cap-Score™ for couples
with women under 40 years of age and most sensitive to the
cost of IVF for couples with women over 40 years of age.
Thus, 55% of the 20 different outcomes estimated, including age-group-specific outcomes, were most sensitive to the

probability of clinical pregnancy with IUI in the absence of the
Cap-Score™.

Discussion
In this study of the potential clinical and cost impact of introducing the Cap-Score™ for clinical management of unexplained infertility, we found an overall increase in clinical
pregnancy rates, an increase in live birth rates in couples with
women over 40 years of age, and across the board cost savings
comparing the Cap-Score™ and timed insemination with the
current standard of care in which the Cap-Score™ is absent.
The increase in clinical pregnancy rates, live birth rates, and
cost savings are higher in older age categories, suggesting
increasing clinical and economic value of the Cap-Score™
with increasing age.
The results were generally robust to sensitivity analyses,
i.e., changing parameters through their plausible ranges did
not result in substantial changes to results. The majority of
outcomes were most sensitive to the probability of clinical
pregnancy with IUI in the absence of the Cap-Score™. This
variable is not directly related to the Cap-Score™. The expected cumulative probability of live birth in women over 35 years
was most sensitive to the live birth rate with IUI, reflecting the
importance of maintenance of successful pregnancies in older
women. As expected, the expected difference in the cost of
IUI between comparators was most sensitive to the cost of
IUI, and the expected difference in the cost of IVF and expected difference in total cost between comparators were both
most sensitive to the cost of IVF.
The potential increase in clinical pregnancy rates, live birth
rates, and cost savings attributable to the Cap-Score™ consistently increase with age because of decreasing probability of
clinical pregnancy with age when women undergo IUI in the
absence of a Cap-Score and the constant probability of clinical
pregnancy with age when women undergo IUI following a
Cap-Score. The Cap-Score™ therefore increases in clinical
and economic value for couples who would otherwise have
a hard time conceiving. The model predicts a potential modest

− $768 $21,210
($10,087–$34,391)
− $894 $25,946
($12,477–$40,924)
− $1253 $33,983
($16,705–$52,003)
− $1366 $42,060
($21,423–$63,241)
> 42

41–42

38–40

35–37

CI credibility interval, SOC standard of care, CS-TI Cap-Score™ with timed intrauterine insemination, Δ change

− $19,189

− $15,111

− $7128

− $6211

− $4006

$24,603 ($14,039–37,358) $20,597
($12,345–$30,331)
$15,766 ($7528–$24,214) − $5444 $27,866 ($15,887–$41,803) $21,655
($12,839–31,034)
$18,129 ($9208–$27,870) −$6364 $32,729
$24,019
($18,657–$48,205%)
($14,340–$35,285)
$20,124 ($9567–$31,450) − $13,859 $41,125 ($23,697–$59,210) $26,014
($15,597–$34,200)
$24,237
− $17,823 $49,445 ($28,240–$71,335) $30,256
($11,756–$36,600)
($18,622–$43,253)

− $595 $18,118 ($8385–$29,724) $14,708 ($6929–$23,111) − $3410

$6484 ($3217–$9820) $5889
($2932–$8735)
$6657
$5889
($3337–$10,095)
($2773–$8599)
$6783
$5889
($3318–$10,272)
($3041–$8929)
$7142
$5889
($3600–$10,786)
($3567–$9657)
$7385
$6019
($3678–$11,100)
($3221–$9444)
< 35

SOC
SOC

CS-TI

Δ

SOC

IUI costs
Age
(years)

IVF costs

Mean (95% CI) IUI costs, IVF costs, and total costs comparing SOC to CS-TI
Table 3

CS-TI

Δ

Total costs

CS-TI

Δ

J Assist Reprod Genet

decrease in live birth rates for women under 40 years of age.
This is due to the fact that population-level rates of IUI success
are projected to be substantially lower than the rates of IUI
success in women receiving the Cap-Score™ algorithm in
clinical practice. Women receiving IUI under a Cap-Score™
algorithm would have a higher chance of IUI success because
a proportion of women whose partners have abnormal CapScores™ (and therefore have a lower chance of IUI success)
would go directly to IVF-ICSI, leaving patients with a higher
chance of IUI success.
The Cap-Score™ has the potential to change the management of male factor infertility and infertility of unknown origin by increasing access, improving outcomes,
and saving money. Given the substantial unmet need for
infertility treatment in the USA—over 50% of the need for
fertility treatment is unmet [29, 30], and just over 60% of
nulliparous women in the USA with current fertility problems have ever used infertility services [4]—the CapScore™ is a potential avenue for increased access.
Increased access to ART will likely result due to cost savings. Because most patients who undergo fertility treatment, in general, and ART, in particular, have to pay out
of pocket due to lack of insurance or under insurance [26,
31], cost savings as a result of the Cap-Score™ may lead to
a larger number of infertile couples being able to afford
and therefore seeking care for infertility. Additionally, because treatment for infertility exerts a substantial burden
due to psychological stress, lost work, and travel costs and
time [31], improved outcomes attributable to the CapScore™ may encourage patients to seek care, thereby increasing access.
The ultimate value of the Cap-Score™ will be depend on
the price of the test as a key factor in its cost-effectiveness.
Currently, the test has not yet been launched, and no price has
been established. Once the price is established, a comparison
of CS-TI to SOC will lead to either a cost-saving or costincreasing scenario accompanied by increased benefit, and
an economic cost-effectiveness assessment of value will require the use of a benchmark or threshold willingness to pay
for additional outcome. Because couples seek fertility treatment to have children, the most important outcome is live
births. To be able to make decisions about the value of the
Cap-Score™ will require estimates of individual’s willingness
to pay for a live birth. A previous contingent valuation study
based on hypothetical scenarios has estimated an ex-ante and
ex-post statistical willingness to pay for a baby at $1.8 million
and $178,000, respectively [32], suggesting that the CapScore will add substantial value. Another study demonstrated
that the couples were willing to pay more for a child than the
calculated direct medical costs [33]. Another study using contingent valuation has also demonstrated a high willingness to
pay for ovarian stimulating hormone in the treatment of infertility [34].
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One limitation of this study is that since the Cap-Score™ is
a novel technology, there are limited data on its use in the
clinical setting. This limits the evidence available to support
the assumptions about the value of two key parameters—
probability of a low Cap-Score™ (compared to a normal
Cap-Score™) and the probability of clinical pregnancy with
IUI following a normal Cap-Score™. This model could be
refined without changing the basic structure and the estimates
updated once there is diffusion of the Cap-Score™ into clinical practice and better data are available.

9.
10.

11.

12.

13.
14.

Conclusion
15.

In this analysis, we project the potential clinical and cost impact of the Cap-Score™ as a clinical tool for management of
unexplained infertility. The Cap-Score™ is projected to improve pregnancy and birth outcomes and save money—thereby potentially increasing access to management of infertility.

16.
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